Comments
yourfanat wrote: I am using another tool for Oracle developers - dbForge Studio for Oracle. This IDE has lots of usefull features, among them: oracle designer, code competion and formatter, query builder, debugger, profiler, erxport/import, reports and many others. The latest version supports Oracle 12C. More information here.

2008 West
DIAMOND SPONSOR:
Data Direct
SOA, WOA and Cloud Computing: The New Frontier for Data Services
PLATINUM SPONSORS:
Red Hat
The Opening of Virtualization
GOLD SPONSORS:
Appsense
User Environment Management – The Third Layer of the Desktop
Cordys
Cloud Computing for Business Agility
EMC
CMIS: A Multi-Vendor Proposal for a Service-Based Content Management Interoperability Standard
Freedom OSS
Practical SOA” Max Yankelevich
Intel
Architecting an Enterprise Service Router (ESR) – A Cost-Effective Way to Scale SOA Across the Enterprise
Sensedia
Return on Assests: Bringing Visibility to your SOA Strategy
Symantec
Managing Hybrid Endpoint Environments
VMWare
Game-Changing Technology for Enterprise Clouds and Applications
Click For 2008 West
Event Webcasts

2008 West
PLATINUM SPONSORS:
Appcelerator
Get ‘Rich’ Quick: Rapid Prototyping for RIA with ZERO Server Code
Keynote Systems
Designing for and Managing Performance in the New Frontier of Rich Internet Applications
GOLD SPONSORS:
ICEsoft
How Can AJAX Improve Homeland Security?
Isomorphic
Beyond Widgets: What a RIA Platform Should Offer
Oracle
REAs: Rich Enterprise Applications
Click For 2008 Event Webcasts
SYS-CON.TV
Today's Top SOA Links


In-Vitro Diagnostics Market Analysis to 2017

NEW YORK, Feb. 19, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

In-Vitro Diagnostics Market Analysis to 2017

http://www.reportlinker.com/p01103486/In-Vitro-Diagnostics-Market-Analysis-to-2017.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_Diagnostic

The global in-vitro diagnostics (IVD) market is going through a very exciting phase, offering immense opportunities for players involved in the business. The market, which on one hand, is struggling to maintain a foothold in the unstable economy of Europe is growing astoundingly at a high double-digit growth rate in emerging economies of India, China, and Brazil.

In their latest research study, "In-Vitro Diagnostics Market Analysis to 2017", RNCOS analysts identified market dynamics in various important regions to highlight the areas offering promising possibilities for companies to boost their growth. The market, which stood at US$ 52.4 Billion in 2012, is expected to grow at a CAGR of 7% during 2012-2017.

In the report, the IVD market has been studied on three distinct levels: Regional, Clinical and Player level. For regional analysis, key IVD markets that together constitute around 95% of the global market, have been profiled. Further, the market has been divided into eight distinct clinical segments and their current and future outlook to 2017 has been analyzed. Through this, our analysts have conducted a thorough opportunity assessment in various clinical segments and highlighted the clinical segments that offer the maximum opportunity for growth in each region.

Besides, our team has also analyzed the revenue generated from each clinical segment to recognize key segments that offer very high growth rates. The study further delves into the business dynamics of major players in the industry that together form more than 70% of the global IVD market. To provide a thorough understanding of the Company's business model, Company's current and historical financials have been analyzed. Also, the Company's revenue from IVD has been depicted with a further breakup by clinical segment. The study also portrays each Company's strengths and weaknesses that will help the reader to better position its company vis-à-vis competition.

1. Analyst View

2. Research Methodology

3. In Vitro Diagnostic Market Overview

3.1 Introduction
3.2 What is In Vitro Diagnostics?
3.3 Market Size and Growth

4. Clinical Segmentation Outlook 2017

(For all clinical segments, the section contains following testing market information)
Market by Region (%), 2012
Market by Players (%), 2012
Testing Market (Billion US$), 2012-2017
4.1 Point-of-Care Diagnostics
4.2 Immunochemistry
4.3 Clinical Chemistry
4.4 Molecular Diagnostics
4.5 Hematology
4.6 Microbiology
4.7 Hemostasis
4.8 Immunohematology

5. Geographical Segmentation Outlook 2017

(For all countries, the section contains following information)
Market by Clinical Segment (%), 2012
In Vitro Diagnostic Market (Billion US$), 2012-2017
Market by Clinical Segment (%), 2017
Key Market Drivers
5.1 America
5.1.1 United States
5.1.2 Canada
5.1.3 Brazil
5.1.4 Mexico
5.2 Europe
5.2.1 Germany
5.2.2 France
5.2.3 Italy
5.2.4 United Kingdom
5.2.5 Spain
5.3 Asia-Pacific
5.3.1 Japan
5.3.2 China
5.3.3 India

6. Industry Trends

6.1 Fast Emerging Niche: Devices to Capture Circulating Tumor Cells
6.2 On the Horizon: Non-Invasive Genetic Tests for Cancer
6.3 Non-Invasive Prenatal Diagnostics Market Witnesses Boom
6.4 Companion Diagnostics Partnerships Gear Up
6.5 Predictive Cancer Diagnostic Test Market Rockets Northwards
6.6 POCT: Expanding Avenues into Multiple Disease Diagnosis

7. Competitive Landscape

(For all players, the section contains following information)
Business Overview
Key Financials
Strengths and Weaknesses
Recent Developments
7.1 Market Share of Top Players
7.2 Key Players
7.2.1 Abbott Laboratories
7.2.2 Alere, Inc.
7.2.3 Becton Dickinson
7.2.4 Bayer HealthCare
7.2.5 Beckman Coulter
7.2.6 Biomerieux
7.2.7 Johnson and Johnson
7.2.8 Life Technologies Corporation
7.2.9 Medtronic, Inc.
7.2.10 Qiagen NV
7.2.11 Roche Holding Ltd
7.2.12 Sysmex Corporation
7.2.13 Siemens HealthCare
7.2.14 Thermo Fisher Scientific

List of Figures:

Figure 3-1: Global - In Vitro Diagnostic Market (Billion US$), 2012-2017
Figure 4-1: Global - In Vitro Diagnostic Market by Clinical Segment (%), 2012
Figure 4-2: Global - Point-of-Care Testing Market by Region (%), 2012
Figure 4-3: Global - Point-of-Care Testing Market by Players (%), 2012
Figure 4-4: Global - Point-of-Care Testing Market (Billion US$), 2012-2017
Figure 4-5: Global - Immunochemistry Testing Market by Region (%), 2012
Figure 4-6: Global - Immunochemistry Testing Market by Players (%), 2012
Figure 4-7: Global - Immunochemistry Testing Market (Billion US$), 2012-2017
Figure 4-8: Global - Clinical Chemistry Testing Market by Region (%), 2012
Figure 4-9: Global - Clinical Chemistry Testing Market by Players (%), 2012
Figure 4-10: Global - Clinical Chemistry Testing Market (Billion US$), 2012-2017
Figure 4-11: Global - Molecular Diagnostics Market by Region (%), 2012
Figure 4-12: Global - Molecular Diagnostics Market by Players (%), 2012
Figure 4-13: Global - Molecular Diagnostics Market (Billion US$), 2012-2017
Figure 4-14: Global - Hematology Testing Market by Region (%), 2012
Figure 4-15: Global - Hematology Testing Market by Players (%), 2012
Figure 4-16: Global - Hematology Testing Market (Billion US$), 2012-2017
Figure 4-17: Global - Microbiology Testing Market by Region (%), 2012
Figure 4-18: Global - Microbiology Testing Market by Players (%), 2012
Figure 4-19: Global - Microbiology Testing Market (Billion US$), 2012-2017
Figure 4-20: Global - Hemostasis Testing Market by Region (%), 2012
Figure 4-21: Global - Hemostasis Testing Market by Players (%), 2012
Figure 4-22: Global - Hemostasis Testing Market (Billion US$), 2012-2017
Figure 4-23: Global - Immunohematology Testing Market by Region (%), 2012
Figure 4-24: Global - Immunohematology Testing Market (Billion US$), 2012-2017
Figure 5-1: Global - In Vitro Diagnostic Market by Region (%), 2012
Figure 5-2: Global - In Vitro Diagnostic Market by Region (%), 2017
Figure 5-3: US - In Vitro Diagnostic Market by Clinical Segment (%), 2012
Figure 5-4: US - In Vitro Diagnostic Market (Billion US$), 2012-2017
Figure 5-5: US - In Vitro Diagnostic Market by Clinical Segment (%), 2017
Figure 5-6: Canada - In Vitro Diagnostic Market by Clinical Segment (%), 2012
Figure 5-7: Canada - In Vitro Diagnostic Market (Billion US$), 2012-2017
Figure 5-8: Canada - In Vitro Diagnostic Market by Clinical Segment (%), 2017
Figure 5-9: Brazil - In Vitro Diagnostic Market by Clinical Segment (%), 2012
Figure 5-10: Brazil - In Vitro Diagnostic Market (Billion US$), 2012-2017
Figure 5-11: Brazil - In Vitro Diagnostic Market by Clinical Segment (%), 2017
Figure 5-12: Mexico - In Vitro Diagnostic Market by Clinical Segment (%), 2012
Figure 5-13: Mexico - In Vitro Diagnostic Market (Billion US$), 2012-2017
Figure 5-14: Mexico - In Vitro Diagnostic Market by Clinical Segment (%), 2017
Figure 5-15: Europe - In Vitro Diagnostic Market by Clinical Segment (%), 2012
Figure 5-16: Europe - In Vitro Diagnostic Market by Country (%), 2012
Figure 5-17: Europe - In Vitro Diagnostic Market (Billion US$), 2012-2017
Figure 5-18: Europe - In Vitro Diagnostic Market by Country (%), 2017
Figure 5-19: Europe - In Vitro Diagnostic Market by Clinical Segment (%), 2017
Figure 5-20: Germany - In Vitro Diagnostic Market by Clinical Segment (%), 2012
Figure 5-21: Germany - In Vitro Diagnostic Market (Billion US$), 2012-2017
Figure 5-22: Germany - In Vitro Diagnostic Market by Clinical Segment (%), 2017
Figure 5-23: France - In Vitro Diagnostic Market by Clinical Segment (%), 2012
Figure 5-24: France - In Vitro Diagnostic Market (Billion US$), 2012-2017
Figure 5-25: France - In Vitro Diagnostic Market by Clinical Segment (%), 2017
Figure 5-26: Italy - In Vitro Diagnostic Market by Clinical Segment (%), 2012
Figure 5-27: Italy - In Vitro Diagnostic Market (Billion US$), 2012-2017
Figure 5-28: Italy - In Vitro Diagnostic Market by Clinical Segment (%), 2017
Figure 5-29: UK - In Vitro Diagnostic Market by Clinical Segment (%), 2012
Figure 5-30: UK - In Vitro Diagnostic Market (Billion US$), 2012-2017
Figure 5-31: UK - In Vitro Diagnostic Market by Clinical Segment (%), 2017
Figure 5-32: Spain - In Vitro Diagnostic Market by Clinical Segment (%), 2012
Figure 5-33: Spain - In Vitro Diagnostic Market (Billion US$), 2012-2017
Figure 5-34: Spain - In Vitro Diagnostic Market by Clinical Segment (%), 2017
Figure 5-35: Japan - In Vitro Diagnostic Market by Clinical Segment (%), 2012
Figure 5-36: Japan - In Vitro Diagnostic Market (Billion US$), 2012-2017
Figure 5-37: Japan - In Vitro Diagnostic Market by Clinical Segment (%), 2017
Figure 5-38: China - In Vitro Diagnostic Market by Clinical Segment (%), 2012
Figure 5-39: China - In Vitro Diagnostic Market (Billion US$), 2012-2017
Figure 5-40: China - In Vitro Diagnostic Market by Clinical Segment (%), 2017
Figure 5-41: India - In Vitro Diagnostic Market by Clinical Segment (%), 2012
Figure 5-42: India - In Vitro Diagnostic Market (Billion US$), 2012-2017
Figure 5-43: India - In Vitro Diagnostic Market by Clinical Segment (%), 2017
Figure 7-1: Global - In Vitro Diagnostic Market by Players (%), 2012
Figure 7-2: Abbott Laboratories - Break up of Revenue by Business Segment (%), 2012
Figure 7-3: Abbott Laboratories - Diagnostic Division Revenue by Segment (%), 2012
Figure 7-4: Alere Inc. - Break up of Revenue by Business Segment (%), 2011
Figure 7-5: Alere Inc. - Diagnostic Division Revenue by Segment (%), 2011
Figure 7-6: Becton Dickinson - Break up of Revenue by Business Segment (%), 2012
Figure 7-7: Becton Dickinson - Diagnostic Division Revenue by Segment (%), 2012
Figure 7-8: Bayer HealthCare - Break up of Revenue by Business Segment (%), 2011
Figure 7-9: Bayer HealthCare - Consumer Health Revenue by Segment (%), 2011
Figure 7-10: Beckman Coulter - Break up of Revenue by Business Segment (%), 2010
Figure 7-11: Beckman Coulter - Diagnostic Division Revenue by Segment (%), 2010
Figure 7-12: Biomerieux - Break up of Revenue by Business Segment (%), 2012
Figure 7-13: Biomerieux - Diagnostic Division Revenue by Segment (%), 2012
Figure 7-14: Johnson & Johnson - Break up of Revenue by Business Segment (%), 2011
Figure 7-15: Life Technologies Corporation - Break up of Revenue by Business Segment (%), 2011
Figure 7-16: Medtronic Inc. - Break up of Revenue by Business Segment (%), 2012
Figure 7-17: Qiagen NV - Break up of Revenue by Business Segment (%), 2011
Figure 7-18: Roche Holdings Ltd - Break up of Revenue by Business Segment (%), 2011
Figure 7-19: Roche Holdings Ltd - Diagnostic Division Revenue by Segment (%), 2011
Figure 7-20: Sysmex Corp. - Break up of Revenue by Business Segment (%), 2012
Figure 7-21: Sysmex Corp. - Diagnostic Division Revenue by Segment (%), 2012
Figure 7-22: Siemens HealthCare - Diagnostic Division Revenue by Segment (%), FY 2012
Figure 7-23: Thermo Fisher Scientific - Break up of Revenue by Business Segment (%), 2011

List of Tables:

Table 4-1: Global - In Vitro Diagnostic Market by Clinical Segment (Billion US$), 2012
Table 4-2: Global - In Vitro Diagnostic Market by Clinical Segment (Billion US$), 2017
Table 5-1: Europe - Percentage of People Aged 65+ Years in Top-5 IVD Markets (2012 & 2017)
Table 7-1: Abbott Laboratories - Key Financials (Million US$), 2010-2012
Table 7-2: Abbott Laboratories - Strengths and Weaknesses
Table 7-3: Alere Inc. - Key Financials (Million US$), 2009-2011
Table 7-4: Alere Inc. - Strengths and Weaknesses
Table 7-5: Becton Dickinson - Key Financials (Million US$), 2010- 2012
Table 7-6: Becton Dickinson - Strengths and Weaknesses
Table 7-7: Bayer HealthCare - Key Financials (Million US$), 2009-2011
Table 7-8: Bayer HealthCare- Strengths and Weaknesses
Table 7-9: Beckman Coulter - Strengths and Weaknesses
Table 7-10: Biomerieux - Key Financials (Million (€), 2010 & 2011
Table 7-11: Biomerieux - Strengths and Weaknesses
Table 7-12: Johnson & Johnson - Key Financials (Million US$), 2010-2012
Table 7-13: Johnson & Johnson - Strengths and Weaknesses
Table 7-14: Life Technologies Corporation - Key Financials (Million US$), 2010-2012
Table 7-15; Life Technologies Corporation - Strengths and Weaknesses
Table 7-16: Medtronic Inc. - Key Financials (Million US$), 2010-2012
Table 7-17; Medtronic Inc. - Strengths and Weaknesses
Table 7-18: Qiagen NV - Key Financials (Million US$), 2009-2011
Table 7-19: Qiagen NV - Strengths and Weaknesses
Table 7-20: Roche Holding Ltd - Key Financials (Million US$), 2010-H1 2012
Table 7-21; Roche Holding Ltd - Strengths and Weaknesses
Table 7-22: Sysmex Corp. - Key Financials (Million US$), 2010- 2012
Table 7-23; Siemens AG - Key Financials (Million €), FY 2010 to FY 2012
Table 7-24: Siemens - Strength and Weaknesses
Table 7-25: Thermo Fisher Scientific - Key Financials (Million US$) 2010-2012 (Q1-Q3)
Table 7-26: Thermo Fisher Scientific Inc. - Strengths and Weaknesses

To order this report:
In_Vitro_Diagnostic Industry:
In-Vitro Diagnostics Market Analysis to 2017

Contact Clare: clare@reportlinker.com
US:(339) 368 6001
Intl:+1 339 368 6001

SOURCE Reportlinker

About PR Newswire
Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Web 2.0 Latest News

The "internet of things" is not coming. It's here.

Driven by the introduction of low-cost "things" that are actually useful, Silicon Valley's promised land of a wirelessly-linked network of ev...

Earlier in the year, Gartner forecast that by year-end 2016, more than 50 percent of global companies will have stored customer-sensitive data in a public cloud platform. These services can scale very quickly, which has made them very popular for applications that have a requirement fo...
In a recent post I posted on DevOps.com, I suggested the term DevOps as a Service (DaaS). Personally I am not a fan of the term. Mainly because DevOps is not a ‘Service’. It is an approach to achieve business objectives by adopting a set of capabilities, namely: Continuous Business Pla...
The goal of any DevOps solution is to optimize multiple processes in an organization. And success does not necessarily require that in executing the strategy everything needs to be automated to produce an effective plan. Yet, it is important that processes are put in place to handle a ...
My favorite writer, Gil Press, sums it up with, “It’s Official: The Internet Of Things Takes Over Big Data As The Most Hyped Technology” where he talks about how Gartner released its latest Hype Cycle for Emerging Technologies, and how big data has moved down the “trough of disillusion...
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
Click to Add our RSS Feeds to the Service of Your Choice:
Google Reader or Homepage Add to My Yahoo! Subscribe with Bloglines Subscribe in NewsGator Online
myFeedster Add to My AOL Subscribe in Rojo Add 'Hugg' to Newsburst from CNET News.com Kinja Digest View Additional SYS-CON Feeds
Publish Your Article! Please send it to editorial(at)sys-con.com!

Advertise on this site! Contact advertising(at)sys-con.com! 201 802-3021




SYS-CON Featured Whitepapers
ADS BY GOOGLE